Mexico: Supreme Court Upholds The Worth Of Formulation Patents

Last Updated: 11 October 2010
Article by Alejandro Luna

Earlier this year the Supreme Court issued welcome clarification on how the Linkage Regulation applies to formulation patents and their publication in the Linkage Gazette.

On 13th January 2010 the Supreme Court issued a groundbreaking decision on the interpretation of the Linkage Regulation, which has been in force for six years. The decision focused on whether the linkage system is limited to compound patents or whether it extends to product patents that cover pharmaceutical formulations. The Supreme Court ruled that formulation patents should be listed in the Linkage Gazette, as only process patents are excluded from the regulation.

Background

On 19th September 2003 the Health Law Regulation and the Industrial Property Regulation were amended to enact the Linkage Regulation in two articles: Article 47bis of the Industrial Property Regulations and Article 167bis of the Health Law Regulations.

The main purpose of these amendments was to establish coordinating rules between the two separate administrative agencies, one empowered to approve the commercialisation of medicines based on safety and efficacy standards and the other responsible for granting patents for inventions. The rationale behind linking these two agencies was to prevent the grant of marketing authorisations that violated exclusive rights.

Article 47bis of the Industrial Property Regulations

This article obliges the Mexican Institute of Industrial Property (IMPI) to publish a special gazette listing patents that cover allopathic drugs, along with their corresponding non-proprietary names. The Linkage Gazette includes products that are the subject of industrial property rights according to their active ingredients and chemical names.

Patents covering manufacturing and formulation processes are expressly excluded from this gazette.

Under the regulation, IMPI must publish and update the Linkage Gazette every six months, listing those patents in force that cover allopathic medicines and containing the following information for each patent:

  • The medicament's generic name.
  • A description of the medicament.
  • The medicament's chemical name.
  • The patent number.
  • The patent's expiration date.
  • The annuities paid.
  • The patent owner.
  • The main claims.
  • Any general comments.

Products are listed in alphabetical order according to their generic name.

Article 167bis of the Health Regulation

This article dictates that applicants for marketing authorisations for allopathic medicines must indicate whether they own a patent or have a licence for a patented active ingredient.

Alternatively, applicants must declare, under oath, that their application does not violate the list of products published in the Linkage Gazette and observes patent law. This declaration is made before the Federal Commission for the Protection and Prevention of Health Risks (COFEPRIS).

Before granting marketing authorisations to third parties other than the title holder, COFEPRIS must also check the listed patents, first by compound and then by the list of patented products issued by IMPI in the Linkage Gazette, which is organised according to the active ingredient's generic name. COFEPRIS must also establish the possibility of requesting additional information from the applicant. If it suspects that patent rights may be violated, COFEPRIS can request technical support from IMPI regarding the scope of the rights.

If COFEPRIS requests technical assistance, IMPI then has 10 days in which to produce an opinion on the scope of the patent and whether the product for which market authorisation is sought falls within it. If IMPI is of the opinion that the product in question falls within the scope of a published patent, the Ministry of Health shall give the applicant an opportunity to show that it has a right to make and sell that product. In the absence of convincing evidence, the application shall be dismissed.

The Roche-Bolar exception

A generic company may apply for a marketing authorisation for a patented medicine listed in the Linkage Gazette without having any rights to it if the patent if is within three years of expiring. This provision allows applicants to begin safety and efficacy tests, interchangeability test, and experiments so that they can be ready to enter the market as soon as the patent expires.

This provision also recognises the confidential nature of the dossier filed with the application for marketing authorisation and states that only the applicant may access this dossier supporting the clinical trials or interchangeability tests.

IMPI'S misinterpretation of the Linkage Gazette

The wording of the Linkage Regulation clearly states that IMPI must publish a gazette every six months that lists all patents in force covering allopathic medicines, according to active ingredient and regardless of whether these patents covered a compound per se or a pharmaceutical composition that includes an active ingredient.

However, since the first Linkage Gazette was published in October 2003, it has included only patents covering compounds per se and has not included patents that cover pharmaceutical compositions and medical – use patents. We consider that IMPI has erred in its interpretation of the regulation.

Olivares and Cia has fashioned a litigation strategy to address this misinterpretation through constitutional actions to obtain the publication of patents covering formulations and second uses. From publication of the first Linkage Gazette to that of the most recent in December 2009, the firm has obtained over 42 precedents from district and circuit courts ordering IMPI to include and publish formulation and medical – use patents in the Linkage Gazette.

The main argument we put before courts when petitioning for the inclusion of such formulations and patents in the gazette rests on the legal and technical definitions of key words in the Linkage Regulation: "allopathic medicines"; "patented products" as opposed to "process patents"; and the interpretation of "according to its active ingredient", where the active ingredient is a reference to the organisation of a list of products and not the subject matter of the list, which is not limited to patents covering active ingredients but covers allopathic medicines with patents in force or products subject to protection based on the Industrial Property Law (as literally stated by the Linkage Regulation and the full name of the Linkage Gazette, which is the Linkage for Allopathic Medicines with Patents in Force).

Listing formulation patents in the Linkage Gazette helps to prevent health authorities from granting marketing authorisations that could fall within the scope of a listed patent. In addition, publication provides the following benefits:

  • A proper application of the linkage system prevents pharmaceutical patents from being infringed, especially given the poor history of enforcing such patents in Mexico.
  • It establishes a valuable source of information for third parties trying to discover the full scope of opposable patents in order to obtain an authorisation for generic drugs.
  • It proves that the patent is in full force and that it covers a product, namely an allopathic medicine. In the event of an infringement action, this publication will help to prove that the patent in question covers a specific pharmaceutical formulation, meaning that no expert opinion will be required during the proceeding. This will save the rights holder time and money in the eventual enforcement of its patents.
  • In case the Linkage Gazette is not observed by the health authorities, the publication of patents is also useful for challenging marketing authorisations for patented formulations granted to third parties without the rights holder's authorisation.
  • The Linkage Gazette is also helpful for public acquisition processes, to confirm that the product to be acquired is covered by a patent, especially when the formulation patent listed in the gazette matches the description of the product in the government's National Formulary for Purchases of Medicines.

Supreme Court decision

Several decisions were issued in favour of rights holders in 2009. However, two out of 16 courts in the First Circuit, which has jurisdiction in Mexico City where such cases are decided, ruled that the linkage system is limited to compound patents.

As provided in the applicable law, the Supreme Court was deemed to have jurisdiction to resolve this impasse and the case was handed over to court's bench responsible for administrative cases. After receiving amicus briefs and memoranda from the pharmaceutical industry – from both innovators and manufacturers of generics – on 13th January 2010 the judges issued a split decision, three to two, in a public hearing declaring that formulation patents should be included in the Linkage Gazette, as per the interpretation of Article 47bis of the Industrial Property Regulation established in over 45 court precedents. The following is an abstract of the Supreme Court's decision:

Case law by contradictory rulings 7/2010 Industrial Property. Patents for allopathic medicines of their claims that do not represent processes for production or formulation of drugs and which in their pharmaceutical composition include an active ingredient, substance or principle, shall be included in the publication referred to in Article 47bis of the Industrial Property Regulations. These patents must be published in the gazette, since they comply with the requirements under Article 47bis of the Industrial Property Regulations, which state that in the case of patents granted to allopathic medicines, IMPI shall publish in the gazette and shall make public a list of products that should be subject to industrial protection according to the active substance or ingredient, which shall specify the duration of the patent in question.

The Supreme Court decision will be considered as a binding precedent to all federal circuit courts and district courts in Mexico, which means that if IMPI fails to include formulation patents in the Linkage Gazette, it would be ordered to list the patent by court orders, provided that the corresponding conditions are met.

This is a landmark case, not only because of its favourable impact on patents law, but also because few cases involving the review of IP rights ever come before the Supreme Court.

Aftermath

Under the Supreme Court's decision, all patents covering allopathic medicines, regardless of whether they are for compounds or formulations, may be published in the Linkage Gazette. For compound patents, the only requirement is that the titleholder or its representative petition IMPI for publication, either directly or through the Chamber of Pharmaceutical Companies. However, the impact of the Supreme Court's decision on formulation patents will remain uncertain until the relevant authorities make their position clear. Legally speaking, administrative authorities such as IMPI and COFEPRIS are not bound to follow judicial case law; however, from a moral and practical standpoint, they tend to observe such precedents.

At the time of writing, it is not yet clear whether IMPI will publish formulation patents in the Linkage Gazette if the rights holder requests this. We would advise applicants to pursue this possibility exhaustively. One positive indication in this regard is that IMPI's general director has talked in the media about "supporting" the Supreme Court's decision.

Any refusal by IMPI to publish a formulation patent can be contested through constitutional actions. The Supreme Court's decision binds the courts to decide on behalf of formulation patents; provided that all necessary criteria are met, these actions should be decided quickly.

Although use and second – use patents were not explicity addressed in the Supreme Court's decision, the precedent should also help rights holders to argue in favour of these types of patent being published in the gazette.

We would like to believe that IMPI will start to include certain formulation patents as a result of the petitions. However, this will be confirmed only once IMPI issues an official communication on the subject or once it publishes the first formulation patent in the Linkage Gazette.

In our view, the ruling helps to clarify the second part of the Linkage Regulation in the sense that published patents (for formulations) should be observed by the Mexican Health Authority before it grants marketing authorisations to third parties, following the linkage system described above.

As the opposing criteria reviewed by the Supreme Court were limited to IMPI's obligation to publish formulation patents in the Linkage Gazette as established in Article 47bis of the Industrial Property Regulation, but not to Article 167bis of the Health Regulation, we await a hard copy of the decision to discover whether the judges also studied or considered the obligations of the Linkage Regulation for COFEPRIS. This hard copy was unavailable at the time of writing; nevertheless, even if no consideration was given to COFEPRIS's obligations (under the general rules and principles for the interpretation of statutory laws), the obligation to observe formulation patents should also apply to it, as the linkage system cannot be disassociated and the obligation to observe formulation patents cannot be imposed on only one of the linked authorities. An alternative scenario would be unreasonable, impractical and, to some extent, illegal.

First published in IAM Life Sciences 250

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.